Globally, Spinal Muscular Atrophy (SMA), a rare genetic neuromuscular disorder, affects approximately 1 in 10,000 live births ...

Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies for spinal muscular atrophy, Duchenne muscular dystrophy and Becker muscular ...

Salanersen, a treatment candidate for spinal muscular atrophy (SMA) now in clinical testing, is safe and was shown to stabilize or improve motor function over at least one year of follow-up in ...

Biogen (NasdaqGS:BIIB) reported one year results for salanersen in children with spinal muscular atrophy, showing clinical improvements and reduced neurodegeneration markers after once yearly dosing.

Former Little Mix star Jesy Nelson has been keeping her fans up-to-date with how her twin baby girls, Story Monroe and Ocean Jade, are getting on, after their spinal muscular atrophy Type 1 diagnosis ...

SMA mutations disrupt spinal cord development, with fewer nerve cells in early stages. SMN protein deficiency leads to a mesodermal fate bias, with fewer motor neurons. Increasing SOX2 pathway ...

Union Minister H D Kumaraswamy has assured assistance for a two-year-old child suffering from a rare genetic disorder after ...

Biogen’s salanersen is now heading into three Phase III trials in SMA.

New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene ...

The company's clinical development plan comprises three global Phase III studies, including two focused on infants and a third for older patients.

This time, her baby did test positive for SMA type 1, a severe neurodegenerative genetic condition that typically results in ...

US biotech major Biogen has presented additional results from the Phase Ib study of salanersen, an investigational novel ...